GEP20032906B - Controlled Release Peroral Pharmaceutical Composition of Levosimendan for Treatment of Congestive Heart Failure - Google Patents

Controlled Release Peroral Pharmaceutical Composition of Levosimendan for Treatment of Congestive Heart Failure

Info

Publication number
GEP20032906B
GEP20032906B GEAP19995639A GEAP1999005639A GEP20032906B GE P20032906 B GEP20032906 B GE P20032906B GE AP19995639 A GEAP19995639 A GE AP19995639A GE AP1999005639 A GEAP1999005639 A GE AP1999005639A GE P20032906 B GEP20032906 B GE P20032906B
Authority
GE
Georgia
Prior art keywords
levosimendan
pharmaceutical composition
treatment
controlled release
heart failure
Prior art date
Application number
GEAP19995639A
Other languages
English (en)
Inventor
Saila Antila
Ilkka Larma
Lasse Lehtonen
Maarit Baeckman
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8551575&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GEP20032906(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Corp filed Critical Orion Corp
Publication of GEP20032906B publication Critical patent/GEP20032906B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Detergent Compositions (AREA)
  • Cosmetics (AREA)
GEAP19995639A 1998-04-23 1999-04-23 Controlled Release Peroral Pharmaceutical Composition of Levosimendan for Treatment of Congestive Heart Failure GEP20032906B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI980901A FI980901A7 (fi) 1998-04-23 1998-04-23 Levosimendaania säädellysti vapauttavia oraalisia koostumuksia

Publications (1)

Publication Number Publication Date
GEP20032906B true GEP20032906B (en) 2003-02-25

Family

ID=8551575

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP19995639A GEP20032906B (en) 1998-04-23 1999-04-23 Controlled Release Peroral Pharmaceutical Composition of Levosimendan for Treatment of Congestive Heart Failure

Country Status (37)

Country Link
US (1) US7045147B1 (enExample)
EP (1) EP1071397B1 (enExample)
JP (2) JP4566402B2 (enExample)
KR (1) KR100960597B1 (enExample)
CN (1) CN1248691C (enExample)
AR (1) AR019096A1 (enExample)
AT (1) ATE258425T1 (enExample)
AU (1) AU756641B2 (enExample)
BG (1) BG64839B1 (enExample)
BR (1) BR9909869A (enExample)
CA (1) CA2329234C (enExample)
CO (1) CO5070607A1 (enExample)
CZ (1) CZ295194B6 (enExample)
DE (1) DE69914472T2 (enExample)
DK (1) DK1071397T3 (enExample)
EA (1) EA002829B1 (enExample)
EE (1) EE04220B1 (enExample)
ES (1) ES2215379T3 (enExample)
FI (1) FI980901A7 (enExample)
GE (1) GEP20032906B (enExample)
HR (1) HRP20000704B1 (enExample)
HU (1) HUP0101458A3 (enExample)
ID (1) ID27987A (enExample)
IL (2) IL138951A0 (enExample)
MX (1) MXPA00010367A (enExample)
NO (1) NO329809B1 (enExample)
NZ (1) NZ507453A (enExample)
PL (1) PL197447B1 (enExample)
PT (1) PT1071397E (enExample)
RS (1) RS49962B (enExample)
SI (1) SI1071397T1 (enExample)
SK (1) SK285427B6 (enExample)
TR (1) TR200003102T2 (enExample)
TW (1) TWI224507B (enExample)
UA (1) UA68376C2 (enExample)
WO (1) WO1999055305A2 (enExample)
ZA (1) ZA200005632B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20011465A0 (fi) * 2001-07-04 2001-07-04 Orion Corp Pyridatsinonijohdannaisen uusi käyttö
BRPI0408323A (pt) * 2003-03-14 2006-03-07 Nirmal Mulye processo para a preparação de compimidos de liberação prolongada
FI20070521A7 (fi) * 2006-11-10 2008-05-11 Atacama Labs Oy Rakeita, tabletteja ja rakeistusmenetelmä
CN102076215A (zh) 2008-06-30 2011-05-25 托卡根公司 5-氟胞嘧啶制剂及其用途
JP2014172850A (ja) * 2013-03-07 2014-09-22 Capsugel Belgium Nv ハードカプセル製剤
CN105784895B (zh) * 2015-10-30 2018-05-22 成都欣捷高新技术开发有限公司 一种用高效液相色谱仪检测左西孟旦中杂质的方法
US11969424B2 (en) 2019-12-16 2024-04-30 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ203684A (en) 1982-04-05 1986-06-11 Merck Sharp & Dohme Granular formulation for the stabilization of unstable drugs or food supplements
US4716042A (en) 1986-06-16 1987-12-29 American Home Products Corporation Stabilized coated aspirin tablets
GB8903130D0 (en) * 1989-02-11 1989-03-30 Orion Yhtymae Oy Substituted pyridazinones
GB2251615B (en) * 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
US5213811A (en) * 1991-09-13 1993-05-25 Sterling Drug Inc. Oral sustained-release drug compositions
GB2266841A (en) * 1992-05-06 1993-11-17 Orion Yhtymae Oy Compounds for use as anti-ischemic medicaments
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
GB9614098D0 (en) * 1996-07-05 1996-09-04 Orion Yhtymae Oy Transdermal delivery of levosimendan
FI973804A7 (fi) * 1997-09-26 1999-03-27 Orion Yhtymae Oy Levosimendaanin oraalisia koostumuksia
FI974578L (fi) * 1997-12-19 1999-06-20 Orion Yhtymae Oyj Menetelmä levosimendaanin antamiseksi
FI980902A7 (fi) * 1998-04-23 1999-10-24 Orion Yhtymae Oyj Levosimendaanin stabiileja koostumuksia

Also Published As

Publication number Publication date
SK15542000A3 (sk) 2001-08-06
WO1999055305A2 (en) 1999-11-04
ATE258425T1 (de) 2004-02-15
CZ20003780A3 (en) 2001-05-16
UA68376C2 (en) 2004-08-16
TWI224507B (en) 2004-12-01
ES2215379T3 (es) 2004-10-01
HRP20000704B1 (hr) 2009-11-30
YU63900A (sh) 2003-07-07
MXPA00010367A (es) 2002-06-04
RS49962B (sr) 2008-09-29
AU3524699A (en) 1999-11-16
SI1071397T1 (en) 2004-06-30
BG104959A (en) 2001-07-31
HUP0101458A3 (en) 2002-05-28
US7045147B1 (en) 2006-05-16
SK285427B6 (sk) 2007-01-04
HUP0101458A2 (hu) 2002-03-28
EP1071397B1 (en) 2004-01-28
CA2329234A1 (en) 1999-11-04
HRP20000704A2 (en) 2001-04-30
AU756641B2 (en) 2003-01-16
PL197447B1 (pl) 2008-03-31
CN1301163A (zh) 2001-06-27
NO329809B1 (no) 2010-12-20
PT1071397E (pt) 2004-06-30
JP4566402B2 (ja) 2010-10-20
ID27987A (id) 2001-05-03
CA2329234C (en) 2008-06-10
PL344078A1 (en) 2001-09-24
EE04220B1 (et) 2004-02-16
EA002829B1 (ru) 2002-10-31
FI980901A7 (fi) 1999-10-24
IL138951A (en) 2006-10-31
KR20010071172A (ko) 2001-07-28
JP2002512946A (ja) 2002-05-08
DE69914472T2 (de) 2004-11-11
BG64839B1 (bg) 2006-06-30
WO1999055305A3 (en) 1999-12-29
JP2010083900A (ja) 2010-04-15
EA200001098A1 (ru) 2001-04-23
NO20005313D0 (no) 2000-10-20
IL138951A0 (en) 2001-11-25
EE200000617A (et) 2002-06-17
BR9909869A (pt) 2000-12-19
CZ295194B6 (cs) 2005-06-15
KR100960597B1 (ko) 2010-06-07
TR200003102T2 (tr) 2001-02-21
FI980901A0 (fi) 1998-04-23
EP1071397A2 (en) 2001-01-31
HK1034032A1 (en) 2001-10-12
NZ507453A (en) 2003-02-28
NO20005313L (no) 2000-11-21
ZA200005632B (en) 2002-01-14
CO5070607A1 (es) 2001-08-28
DK1071397T3 (da) 2004-04-05
DE69914472D1 (de) 2004-03-04
CN1248691C (zh) 2006-04-05
AR019096A1 (es) 2001-12-26

Similar Documents

Publication Publication Date Title
AU5303996A (en) Pharmaceutical compositions for controlled release of soluble receptors
EP1842567A3 (en) Intraluminal device with a coating containing a therapeutic agent
AR016798A1 (es) Uso de una cepa de lactobacillus para la elaboracion de un medicamento
DE68928897D1 (de) Verfahren und system zur empfängnisverhütung
UA29563C2 (uk) Мікрокапсула для тривалого вивільнення фізіологічно активного пептиду
WO2001043749A3 (en) Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
GB9408775D0 (en) Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
GR3017691T3 (en) Oral composition for the treatment of inflammatory bowel diseases.
IL134268A0 (en) Pharmaceutical compositions containing vitamin d and calcium, their preparation and therapeutic use
NZ514129A (en) Tolperison-containing, pharmaceutical preparation for oral administration
MX9708803A (es) Compuestos biaromaticos de propinilo o dienilo.
BR0111506A (pt) Complexos de droga macromoleculares e composições contendo os mesmos
GEP20032906B (en) Controlled Release Peroral Pharmaceutical Composition of Levosimendan for Treatment of Congestive Heart Failure
HUP9802897A3 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
GR3032224T3 (en) Therapeutic agent for threatened abortion.
EP0273407A3 (en) Medicine for improving the specific properties of blood
SE9501671D0 (sv) Method and composition for prevention of posterior capsule opacification
AU3423493A (en) Methods and compositions for reducing blood loss
DE69431430D1 (de) Faktor XIII zur Behandlung von Hautwunden
EP0880967A3 (de) Nephroprotektive Arzneimittel
Mehra et al. Role of tromaril--a new anti-inflammatory drug in eye diseases
CA2159609A1 (en) Factor xiii for treatment of skin wounds
HU9802896D0 (en) Optically active piperidinoalkyl-4h-1,2,4-oxadiazine derivative, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
IT1270958B (it) Composizioni farmaceutiche a base di nimesulide, somministrabili per via orale, non gastrolesive e/o a rilascio controllato
IL103499A0 (en) Pharmaceutical compositions for treating anxiety in benzodiazepine withdrawn patients